Equities analysts predict that aTyr Pharma, Inc. (NASDAQ:LIFE) will report ($0.43) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for aTyr Pharma’s earnings, with the lowest EPS estimate coming in at ($0.48) and the highest estimate coming in at ($0.39). aTyr Pharma reported earnings per share of ($0.53) during the same quarter last year, which suggests a positive year-over-year growth rate of 18.9%. The business is scheduled to announce its next earnings results on Thursday, March 15th.
On average, analysts expect that aTyr Pharma will report full-year earnings of ($1.93) per share for the current fiscal year, with EPS estimates ranging from ($1.98) to ($1.88). For the next year, analysts forecast that the firm will report earnings of ($1.78) per share, with EPS estimates ranging from ($2.05) to ($1.37). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that cover aTyr Pharma.
aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.07.
A number of equities research analysts have weighed in on LIFE shares. ValuEngine cut shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Zacks Investment Research cut shares of aTyr Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, January 17th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. aTyr Pharma presently has a consensus rating of “Hold” and an average target price of $4.81.
Large investors have recently bought and sold shares of the company. Artal Group S.A. purchased a new stake in shares of aTyr Pharma during the third quarter valued at approximately $1,263,000. Victory Capital Management Inc. purchased a new stake in shares of aTyr Pharma during the third quarter valued at approximately $455,000. Finally, Dimensional Fund Advisors LP grew its holdings in shares of aTyr Pharma by 44.1% during the third quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock valued at $423,000 after buying an additional 25,676 shares during the last quarter. Hedge funds and other institutional investors own 58.00% of the company’s stock.
Shares of aTyr Pharma (LIFE) opened at $3.40 on Friday. The company has a quick ratio of 9.49, a current ratio of 9.49 and a debt-to-equity ratio of 0.17. aTyr Pharma has a fifty-two week low of $2.30 and a fifty-two week high of $6.50.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/13/atyr-pharma-inc-life-expected-to-post-earnings-of-0-43-per-share.html.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Get a free copy of the Zacks research report on aTyr Pharma (LIFE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.